IDYA IDEAYA Biosciences, Inc
IDEAYA Biosciences, Inc (IDYA) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $1.28 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.0% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About IDEAYA Biosciences, Inc
IDEAYA is a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
Sector
Healthcare
Industry
Biotechnology